ulcerative colitis

PWE-053 Outcomes of anti-tnf versus vedolizumab therapy for ulcerative colitis: the leeds experience
AJ Johnston, M Lenti, A O’Connor, C Selinger, AC Ford, PJ Hamlin

Gut Jul 2017, 66 (Suppl 2) A152; DOI: 10.1136/gutjnl-2017-314472.298
PTH-102 Association of gut microbiota with mucosal inflammation in ulcerative colitis
MN Quraishi, A Rossiter, B Chung, M Beaumont, E Liaskou, R Horniblow, A Beggs, D Withers, S Ghosh, C Tselepis, G Hirschfield, T Iqbal

Gut Jul 2017, 66 (Suppl 2) A257; DOI: 10.1136/gutjnl-2017-314472.501
AODWE-002 Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of gemini 1 completers rolling into the gemini open-label extension study
A Kaser, A James, on behalf of the GEMINI open-label extension study authors

Gut Jul 2017, 66 (Suppl 2) A120; DOI: 10.1136/gutjnl-2017-314472.237
PTH-106 Phenotypic characterisation of elderly – onset inflammatory bowel disease – ibd at 60 and beyond
U Nosegbe, B Miller, B Crooks, J Scott, J Limdi

Gut Jul 2017, 66 (Suppl 2) A258-A260; DOI: 10.1136/gutjnl-2017-314472.505
Genome-wide association scan in north Indians reveals three novel HLA-independent risk loci for ulcerative colitis
Garima Juyal, Sapna Negi, Ajit Sood, Aditi Gupta, Pushplata Prasad, Sabyasachi Senapati, Jacques Zaneveld, Shalini Singh, Vandana Midha, Suzanne van Sommeren, Rinse K Weersma, Jurg Ott, Sanjay Jain, Ramesh C Juyal, B K Thelma

Gut Apr 2015, 64 (4) 571-579; DOI: 10.1136/gutjnl-2013-306625
AODWE-007 Real world data on the effectiveness and safety of vedolizumab in the treatment of crohn’s disease and ulcerative colitis: the edinburgh experience
N Plevris, TA Manship, A Deekae, GR Jones, CL Noble, J Satsangi, AG Shand, ID Arnott, CW Lees

Gut Jul 2017, 66 (Suppl 2) A123-A124; DOI: 10.1136/gutjnl-2017-314472.242
Vedolizumab safety in pregnancy and newborn outcomes
Mette Julsgaard, Jens Kjeldsen, Daniel C Baumgart

Gut Oct 2017, 66 (10) 1866-1867; DOI: 10.1136/gutjnl-2016-313444
Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study
A Hochart, C Gower-Rousseau, H Sarter, M Fumery, D Ley, C Spyckerelle, L Peyrin-Biroulet, J-E Laberenne, F Vasseur, G Savoye, D Turck

Gut Nov 2017, 66 (11) 1912-1917; DOI: 10.1136/gutjnl-2016-311970
Interleukin 13-mediated colitis in the absence of IL-4Rα signalling
Jennifer C Hoving, Antony J Cutler, Mosiuoa Leeto, William G C Horsnell, Benjamin G Dewals, Natalie E Nieuwenhuizen, Frank Brombacher

Gut Nov 2017, 66 (11) 2037-2039; DOI: 10.1136/gutjnl-2016-313208
Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn's disease from UC
Amanda E Starr, Shelley A Deeke, Zhibin Ning, Cheng-Kang Chiang, Xu Zhang, Walid Mottawea, Ruth Singleton, Eric I Benchimol, Ming Wen, David R Mack, Alain Stintzi, Daniel Figeys

Gut Sep 2017, 66 (9) 1573-1583; DOI: 10.1136/gutjnl-2015-310705

Main menu

ulcerative colitis

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

ulcerative colitis

Pages